Literature DB >> 16140949

Cancer chemotherapy by deoxynucleotide depletion and E2F-1 elevation.

Ajin Wang1, Chiang J Li, Prem V Reddy, Arthur B Pardee.   

Abstract

We propose that the lethality of commonly used anticancer drugs, e.g., methotrexate and cis-platinum are due, at least in part, to an increase of the E2F-1-mediated apoptotic cascade. The drugs directly or indirectly decrease deoxynucleoside triphosphates. The E2F family acts to provide control of S phase by transcribing genes required for deoxynucleoside triphosphate and DNA synthesis. Thus, a mechanism for control of E2F-1 is essential, a signal safeguarding against aberrant or uncontrolled cell proliferation. We have proposed a feedback control by NTPs that down-regulates E2F-1. Here, we provide evidence in support of this hypothesis.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16140949     DOI: 10.1158/0008-5472.CAN-05-0888

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  10 in total

1.  Functional analysis of LOXL2 in pancreatic carcinoma.

Authors:  Felix Rückert; Peer Joensson; Hans-Detlev Saeger; Robert Grützmann; Christian Pilarsky
Journal:  Int J Colorectal Dis       Date:  2009-12-09       Impact factor: 2.571

Review 2.  A comprehensive review of the roles of E2F1 in colon cancer.

Authors:  Zejun Fang; Min Lin; Chunxiao Li; Hong Liu; Chaoju Gong
Journal:  Am J Cancer Res       Date:  2020-03-01       Impact factor: 6.166

3.  Suppression of antifolate resistance by targeting the myosin Va trafficking pathway in melanoma.

Authors:  María Piedad Fernández-Pérez; María F Montenegro; Magalí Sáez-Ayala; Luis Sánchez-del-Campo; Antonio Piñero-Madrona; Juan Cabezas-Herrera; José Neptuno Rodríguez-López
Journal:  Neoplasia       Date:  2013-07       Impact factor: 5.715

4.  Promoting E2F1-mediated apoptosis in oestrogen receptor-α-negative breast cancer cells.

Authors:  María F Montenegro; María Del Mar Collado-González; María Piedad Fernández-Pérez; Manel B Hammouda; Lana Tolordava; Mariam Gamkrelidze; José Neptuno Rodríguez-López
Journal:  BMC Cancer       Date:  2014-07-26       Impact factor: 4.430

5.  Low Doses of Cisplatin Induce Gene Alterations, Cell Cycle Arrest, and Apoptosis in Human Promyelocytic Leukemia Cells.

Authors:  Venkatramreddy Velma; Shaloam R Dasari; Paul B Tchounwou
Journal:  Biomark Insights       Date:  2016-08-24

6.  Positive regulation of ataxia-telangiectasia-mutated protein (ATM) by E2F transcription Factor 1 (E2F-1) in cisplatin-resistant nasopharyngeal carcinoma cells.

Authors:  Zun-Yan Zhou; Ji-Yuan Yang; Cheng-Ze Shao; Fei Luo; Wei Du
Journal:  World J Surg Oncol       Date:  2022-03-18       Impact factor: 2.754

7.  E2F1 Affects the Therapeutic Response to Neoadjuvant Therapy in Breast Cancer.

Authors:  Xinxing Ye; Jie Zhou; Dandan Tong; Dandan Wang; Hui Wang; Jixue Guo; Xinmei Kang
Journal:  Dis Markers       Date:  2022-09-17       Impact factor: 3.464

8.  Integrated analysis of DNA methylation and gene expression reveals specific signaling pathways associated with platinum resistance in ovarian cancer.

Authors:  Meng Li; Curt Balch; John S Montgomery; Mikyoung Jeong; Jae Hoon Chung; Pearlly Yan; Tim H M Huang; Sun Kim; Kenneth P Nephew
Journal:  BMC Med Genomics       Date:  2009-06-08       Impact factor: 3.063

Review 9.  Targeting the epigenetic machinery of cancer cells.

Authors:  M F Montenegro; L Sánchez-del-Campo; M P Fernández-Pérez; M Sáez-Ayala; J Cabezas-Herrera; J N Rodríguez-López
Journal:  Oncogene       Date:  2014-01-27       Impact factor: 9.867

10.  Lobaplatin inhibits the proliferation of hepatollular carcinoma through p53 apoptosis axis.

Authors:  Ying Wang; Wen-Ling Zheng; Wen-Li Ma
Journal:  Hepat Mon       Date:  2012-10-11       Impact factor: 0.660

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.